Date	Event
April, 2003	Company Founded as Maryland Biotherapeutics (MBTI), Robert Ting, Ph.D., named President
March, 2004	Executed license with UMBI for Transition-State Vaccine (TSV) and Genetic Adjuvant technology
May, 2004	MBTI renamed Profectus BioSciences, Inc.
November, 2004	$2.3M in seed money raised (convertible debt)
January, 2005	Operations commenced
April, 2005	Option agreement signed between Profectus BioSciences and Wyeth to evaluate TSV technology ($5.3 million)
July, 2005	Executed license with UMB and UMBI for AIM Therapy Technology
August, 2005	First NIH RO1 grant awarded for TSV technology ($350,000)
September, 2005	Profectus names Joe Berardino as CEO.
November, 2005	Material Transfer Agreement signed with Leading Veterinary Company for Genetic Adjuvant technology for veterinary applications e.g. Avian Flu, Rabies, etc.
January, 2006	CRADA signed with NCI for Antiviral MAbs
March, 2006	Profectus honored with Incubator Company of the Year Award (MD)
April, 2006	$5.3M Series A round (including conversion of convertible debt)
October, 2006	First Maryland Industrial Partnership (MIPS) grant awarded ($200,000) for AIM Therapy
January, 2007	Second MIPS grant awarded ($100,000) for Genetic Adjuvant technology
March, 2007	Profectus honored as the Best Academic/ Industry Collaboration Award by the Greater Baltimore Committee.
June, 2007	$3M Private Placement of Convertible Notes and Warrants
June, 2007	First NIH Phase 1 SBIR grant awarded for Genetic Adjuvant technology ($300,000)
July, 2007	Second NIH Phase 1 SBIR grant awarded for AIM Therapy technology ($200,000)
January, 2008	Profectus names Shawn Patrick O'Brien as President, CEO.